Feedback

Jubilant Ingrevia Reports Q1 FY25 Unaudited Financial Results, Highlights Growth

Jubilant Ingrevia Limited (JUBLINGREA), a global life science products and innovative solutions provider, announced its unaudited standalone and consolidated financial results for the first quarter of the fiscal year 2024-25 (Q1 FY25), ending June 30, 2024.

Financial Highlights:

The company reported growth in both standalone and consolidated revenue from operations. Key drivers included strong performance in the specialty chemicals and nutrition & health solutions segments.

• Revenue Growth: Both standalone and consolidated revenue increased compared to the same quarter last year.
• Profitability: The company maintained healthy profit margins despite rising input costs.
• Segmental Performance: The specialty chemicals segment remained a major contributor to the company's overall growth.

Investor Conference Call:

Jubilant Ingrevia has scheduled an investor conference call on July 16th, 2024, to discuss the Q1 FY25 results in detail. Investors and analysts will have the opportunity to ask questions about the company's performance and future plans.

Additional Notes: